Autolus Therapeutics plc Accumulated Other Comprehensive Income
Autolus Therapeutics plc (AUTL) had Accumulated Other Comprehensive Income of -$6.10 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.10M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$6.63M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$5.36M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$4.92M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$6.10M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$6.63M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$5.36M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$4.92M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $862.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$18.11M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$29.17M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$898.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$27.91M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$28.93M 10-Q · filed 2024-05-17 |
| 2023-12-31 | -$28.99M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$33.79M 10-K · filed 2024-03-21 |
| 2023-06-30 | -$27.96M 10-K · filed 2024-03-21 |
| 2023-03-31 | -$33.26M 10-K · filed 2024-03-21 |
| 2022-12-31 | -$38.90M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$47.56M 10-K · filed 2024-03-21 |
| 2022-06-30 | -$33.51M 10-K · filed 2024-03-21 |
| 2022-03-31 | -$16.02M 10-K · filed 2024-03-21 |
| 2021-12-31 | -$8.57M 20-F · filed 2023-03-07 |
| 2021-03-31 | -$4.59M 6-K · filed 2021-05-06 |
| 2020-12-31 | -$5.86M 20-F · filed 2022-03-10 |
| 2020-09-30 | -$17.30M 6-K · filed 2020-11-05 |
| 2020-06-30 | -$28.21M 6-K · filed 2020-08-06 |
| 2020-03-31 | -$26.39M 6-K · filed 2020-05-07 |
| 2019-12-31 | -$8.69M 20-F · filed 2021-03-04 |
| 2019-09-30 | -$28.35M 6-K · filed 2019-11-07 |
| 2019-06-30 | -$19.31M 6-K · filed 2019-08-08 |
| 2018-12-31 | -$15.49M 20-F · filed 2020-03-03 |
| 2018-09-30 | -$9.92M 20-F · filed 2019-02-25 |
| 2017-09-30 | -$3.85M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |